Insmed’s Brensocatib Receives the US FDA’s Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis
Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults
Shots:
- The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations
- Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21
- Brensocatib is a novel oral, reversible DPP1 inhibitor, currently being developed for the treatment of bronchiectasis and other inflammatory diseases
Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter